Hospital and outpatient health services utilization among HIV-infected children in care 2000-2001

Medical Care

Volumn 43, Issue 9 SUPPL., 2005, Pages

  Rutstein, Richard M ^a   Gebo, Kelly A ^b   Siberry, George K ^b   Flynn, Patricia M ^c   Spector, Stephen A ^d   Sharp, Victoria L ^e   Fleishman, John A ^f  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^f AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

Antiretroviral therapy; Children; HIV; Hospital admission; Resource use

Indexed keywords

EID: 24944475144     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000175568.79432.d1     Document Type: Article

References (33)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999;282:2220-2226.
3. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-1942.
4. Canani RB, Spagnuolo MI, Cirillo P, et al. Decreased needs for hospital care and antibiotics in children with advanced HIV-1 disease after protease inhibitor-containing combination therapy. AIDS. 1999;13:1005-1006.
5. de Martino M, Tovo PA, Balducci M, et al., for the Italian Register for HIV Infection in Children and the Italian National AIDS Registry. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA. 2000;284:190-197.
6. Gortmaker SL, Hughes M, Cervia J, et al. The Pediatric AIDS Clinical Trials Group. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
7. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS. 1997;11:F101-F105.
8. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med. 1997;336:1531-1532.
9. Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet. 2003;362:1605-1611.
10. Tovo PA, de Martino M, Gabiano C, et al. Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections in Children. Lancet. 1992;339:1249-1253.
11. The Working Group on Antiretroviral Therapy. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Therapy. Available at: http://www.aidsinfonihgov/guidelines. Accessed June 20, 2003.
12. Long JS. Regression Models for Categorical and Limited Dependent Variables. Thousand Oaks, CA: Sage Publications; 1997.
13. Liang KY, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 1986;1986:13-22.
14. The HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immun Defic Syndr. 2002;30:21-26.
15. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-823.
16. Baum SE, Morris JT, Gibbons RV, et al. Reduction in human immunodeficiency virus patient hospitalizations and nontraumatic mortality after adoption of highly active antiretroviral therapy. Mil Med. 1999;164:609-612.
17. Gebo KA, Diener-West M, Moore RD. Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immun Defic Syndr. 2001;27:143-152.
18. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305-2315.
19. Conviser R, Grant CM, Coye MJ. Pediatric acquired immunodeficiency syndrome hospitalizations in New Jersey. Pediatrics. 1991;87:642-653.
20. Hsia DC, Fleishman JA, East JA, et al. Pediatric human immunodeficiency virus infection. Recent evidence on the utilization and costs of health services. Arch Pediatr Adolesc Med. 1995;149:489-496.
21. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
22. Cherry DK, Burt CW, Woodwell DA. National Ambulatory Medical Care Survey: 2001 summary. Adv Data. 2003;337:1-44.
23. Dovey S, Weitzman M, Fryer G, et al. The Ecology of Medical Care for Children in the United States. Pediatrics. 2003;111:1024-1029.
24. The European Collaborative Study. Hospitalization of children born to human immunodeficiency virus-infected women in Europe. Pediatr Infect Dis J. 1997;16:1151-1156.
25. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003;327:1019-1020.
26. American Academy of Pediatrics CoPaAM. Recommendations for Preventative Pediatric Health Care. Pediatrics. 2000;105:645-646.
27. Schoenbaum EE, Lo Y, Floris-Moore M. Predictors of hospitalization for HIV-positive women and men drug users, 1996-2000. Public Health Rep. 2002;117(suppl 1):S60-S66.
28. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS. 1999;13:963-969.
29. Moore RD, Chaisson RE. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. J Acquir Immun Defic Syndr Hum Retrovirol. 1997;14:223-231.
30. McNaghten AD, Hanson DL, Dworkin MS, et al. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immun Defic Syndr. 2003;32:499-505.
31. Gebo K, Fleishman J, Conviser R, et al. Racial and gender disparities in receipt of HAART persist in a multi-state sample of HIV patients in 2001. J Acquir Immun Defic Syndr. 2005;38:96-103.
32. Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med. 1996;334:701-706.
33. Kitahata MM, Van Rompaey SE, Shields AW. Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy. J Acquir Immun Defic Syndr. 2000;24:106-114.